Impact of some antiviral drugs on health care utilization for patients with COVID-19: a systematic review and meta-analysis

References

• World Health Organization. Coronavirus disease-19 (COVID-19) dashboard. 2023. [Internet]. 2023 [cited 2023 Aug 10]. Available from: https://covid19.who.int/.
   Google Scholar
• Carroll WD, Strenger V, Eber E, et al. European and United Kingdom COVID-19 pandemic experience: the same but different. Paediatr Respir Rev. 2020;35:50–56. doi: 10.1016/j.prrv.2020.06.012
   PubMed Web of Science ®Google Scholar
• Bojdani E, Rajagopalan A, Chen A, et al. COVID-19 pandemic: impact on psychiatric care in the United States. Psychiatry Res. 2020;289:113069. doi: 10.1016/j.psychres.2020.113069
   PubMed Web of Science ®Google Scholar
• Ansems K, Grundeis F, Dahms K, et al. Remdesivir for the treatment of COVID-19 (review). Cochrane Database Syst Rev. 2021;8(8): CD014962. doi: 10.1002/14651858.CD014962
   PubMedGoogle Scholar
• Flisiak R, Flisiak-Jackiewicz M, Rzymski P, et al. Tocilizumab for the treatment of COVID-19. Exp Rev Anti-Infective Ther. [cited 2023 Aug 2];21:791–797. InternetAvailable from. doi: 10.1080/14787210.2023.2226867.
   PubMed Web of Science ®Google Scholar
• Wen W, Chen C, Tang J, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54:516–523. doi: 10.1080/07853890.2022.2034936
   PubMed Web of Science ®Google Scholar
• Okoli GN, Rabbani R, Al-Juboori A, et al. Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. Expert Rev Anti Infect Ther. 2022;20(2):267–278. doi: 10.1080/14787210.2021.1961579
   PubMed Web of Science ®Google Scholar
• Wai A-C, Chan CY, Cheung A-L, et al. Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg Health West Pac [Internet]. 2023. [cited 2023 Mar 2];30:100602. Available from: https://linkinghub.elsevier.com/retrieve/pii/S266660652200217610.1016/j.lanwpc.2022.100602
   PubMedGoogle Scholar
• Eltayb WA, Abdalla M, Rabie AM. Novel Investigational Anti-SARS-CoV-2 agent ensitrelvir “s-217622”: a very promising potential universal broad-spectrum antiviral at the therapeutic frontline of coronavirus species. ACS Omega [Internet]. 2023. [cited 2023 Jul 25];8:5234–5246. doi: 10.1021/acsomega.2c03881
   PubMedGoogle Scholar
• Rabie AM, Eltayb WA. Potent dual polymerase/exonuclease inhibitory activities of antioxidant aminothiadiazoles against the covid-19 omicron virus: a promising in silico/in vitro repositioning research study. Mol Biotechnol. [Internet] 2023 [cited 2023 Jul 25]. 10.1007/s12033-022-00551-8
   PubMed Web of Science ®Google Scholar
• Rabie AM. Efficacious preclinical repurposing of the nucleoside analogue Didanosine against COVID-19 polymerase and exonuclease. ACS Omega [Internet]. 2022 [cited 2023 Jul 25]. 7:21385–21396. doi: 10.1021/acsomega.1c07095.
   PubMed Web of Science ®Google Scholar
• Rabie AM, Abdalla M. Evaluation of a series of nucleoside analogs as effective anticoronaviral-2 drugs against the omicron-B.1.1.529/BA.2 subvariant: A repurposing research study. Med Chem Res [Internet]. 2023 [cited 2023 Jul 25];32:326–341. doi: 10.1007/s00044-022-02970-3
   PubMedGoogle Scholar
• Rabie AM, Abdalla M. Forodesine and riboprine exhibit strong Anti-SARS-CoV-2 repurposing potential: In Silico and in vitro studies. ACS Bio Med Chem Au [Internet]. 2022 [cited 2023 Jul 25];2:565–585. doi: 10.1021/acsbiomedchemau.2c00039
   PubMedGoogle Scholar
• Rabie AM. Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles. Chem Biol Interact [Internet]. 2021 [[cited 2023 Jul 25]];343:109480. https://www.sciencedirect.com/science/article/pii/S000927972100116210.1016/j.cbi.2021.109480
   PubMed Web of Science ®Google Scholar
• Rabie AM. Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication. ACS Omega Internet 2022;7:2960–2969. [cited 2023 Jul 25]. doi: 10.1021/acsomega.1c05998.
   PubMed Web of Science ®Google Scholar
• Rabie AM. Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19. Current Res Pharmacol Drug Discov. 2021 [[cited 2023 Jul 25]];2:100055. InternetAvailable from: https://www.sciencedirect.com/science/article/pii/S259025712100042010.1016/j.crphar.2021.100055
   PubMedGoogle Scholar
• Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167–173. doi: 10.1016/j.ejphar.2014.01.064
   PubMed Web of Science ®Google Scholar
• Santoro , MG, and Carafoli , E Remdesivir: From Ebola to COVID-19 Biochem Biophys Res Commun. [Internet]. 2021 [cited 2023 Aug 5]; 538:145–150. https://www.sciencedirect.com/science/article/pii/S0006291X2032087810.1016/j.bbrc.2020.11.043
   Web of Science ®Google Scholar
• Bakheit AH, Darwish H, Darwish IA, et al. Chapter Three - Remdesivir. In: Al-Majed A, editor. Profiles of drug substances, excipients and related methodology [Internet]. Academic Press; 2023 [cited 2023 Aug 5]. p. 71–108. Available from; https://www.sciencedirect.com/science/article/pii/S187151252200017610.1016/bs.podrm.2022.11.003
   Google Scholar
• Kaplan SS, Hicks CB. Lopinavir/Ritonavir in the treatment of human immunodeficiency virus infection. Expert Opin Pharmacother [Internet]. 2005. [cited 2023 Aug 5]; 6:1573–1585 doi: 10.1517/14656566.6.9.1573.
   PubMed Web of Science ®Google Scholar
• Painter GR, Natchus MG, Cohen O, et al. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol 2021;50:17–22. https://www.sciencedirect.com/science/article/pii/S1879625721000663 InternetAvailable from: [cited 2023 Aug 5] 10.1016/j.coviro.2021.06.003.
   PubMed Web of Science ®Google Scholar
• Halford B. The path to paxlovid. ACS Cent Sci [Internet]. 2022 [cited 2023 Aug 5];8:405–407. doi: 10.1021/acscentsci.2c00369.
   PubMed Web of Science ®Google Scholar
• Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors | Nature [Internet]. [cited 2023 Aug 5]. Available from: https://www.nature.com/articles/s41586-020-2223-y.
   Google Scholar
• Mahajan L, Singh AP, Null G. Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: a prospective randomised study. Indian J Anaesth. 2021;65(13):S41–S46. doi: 10.4103/ija.IJA_149_21
   PubMed Web of Science ®Google Scholar
• Slomski A. No benefit for lopinavir-ritonavir in severe COVID-19. JAMA. 2020;323:1999. doi: 10.1001/jama.2020.6793
   Web of Science ®Google Scholar
• Nyirenda JL, Sofroniou M, Toews I, et al. Fluvoxamine for the treatment of COVID-19. Cochrane Database Syst Rev. 2022;9(9): CD015391. doi: 10.1002/14651858.CD015391
   PubMedGoogle Scholar
• Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281–293. doi: 10.1016/S0140-6736(22)02597-1
   PubMed Web of Science ®Google Scholar
• Reis S, Metzendorf MI, Kuehn R, et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database Syst Rev. 2022;9(9): CD015395. doi: 10.1002/14651858.CD015395.pub2
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLOS Med. 2021;18(3):e1003583. doi: 10.1371/journal.pmed.1003583
   PubMed Web of Science ®Google Scholar
• Haddaway NR, Page MJ, Pritchard CC, et al. PRISMA2020: an r package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022;18:e1230. doi: 10.1002/cl2.1230
   PubMedGoogle Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. doi: 10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690–1691. doi: 10.1001/jama.280.19.1690
   PubMed Web of Science ®Google Scholar
• Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011 [cited 2023 Jul 31];342(feb22 1):d671. InternetAvailable from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043109/
   PubMedGoogle Scholar
• COVID-19 Hospitalizations [Internet]. [cited 2023 Jul 30]. Available from: https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html.
   Google Scholar
• Gao J, Feng L, Li Y, et al. A systematic review and meta-analysis of the association between SARS-CoV-2 vaccination and myocarditis or pericarditis. Am J Prev Med. 2023;64(2):275–284. doi: 10.1016/j.amepre.2022.09.002
   PubMed Web of Science ®Google Scholar
• Cheema HA, Jafar U, Sohail A, et al. Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: a systematic review and meta‐analysis. J med virol. 2023 [cited 2023 Mar 6]; 95(2). InternetAvailable from: https://onlinelibrary.wiley.com/doi/10.1002/jmv.28471
   Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi: 10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• Sedgwick P, Marston L. How to read a funnel plot in a meta-analysis. BMJ. 2015;351:h4718. doi: 10.1136/bmj.h4718
   PubMed Web of Science ®Google Scholar
• Hussain Alsayed HA, Saheb Sharif-Askari F, Saheb Sharif-Askari N, et al. Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: a retrospective cohort study. PLoS One. 2021;16:e0258643. doi: 10.1371/journal.pone.0258643
   PubMed Web of Science ®Google Scholar
• Tsuzuki S, Hayakawa K, Uemura Y, et al. Effectiveness of remdesivir in hospitalized nonsevere patients with covid-19 in japan: a large observational study using the COVID-19 registry Japan. Inter J Infect Dis [Internet] 2022; [cited 2023 Mar 2] 118:119–125. https://linkinghub.elsevier.com/retrieve/pii/S120197122200118710.1016/j.ijid.2022.02.039.
   PubMed Web of Science ®Google Scholar
• Boglione L, Dodaro V, Meli G, et al. Remdesivir treatment in hospitalized patients affected by COVID‐19 pneumonia: a case‐control study. J med virol. 2022 [cited 2023 Mar 9];94(8):3653–3660. InternetAvailable from: https://onlinelibrary.wiley.com/doi/10.1002/jmv.27768
   PubMed Web of Science ®Google Scholar
• Russo A, Binetti E, Borrazzo C, et al. Efficacy of remdesivir-containing therapy in hospitalized COVID-19 patients: a prospective clinical experience. J Clin Med. 2021;10(17):3784. doi: 10.3390/jcm10173784
   PubMed Web of Science ®Google Scholar
• Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial [Internet]. Infectious Diseases (Except HIV/AIDS); 2022 [cited 2023 Mar 31]. Available from: http://medrxiv.org/lookup/doi/10.1101/2022.03.30.22273206.
   Google Scholar
• Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCovery): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22(2):209–221. doi: 10.1016/S1473-3099(21)00485-0
   PubMed Web of Science ®Google Scholar
• Ramos-Rincon J-M, López-Carmona M-D, Cobos-Palacios L, et al. Remdesivir in very old patients (≥80 years) hospitalized with covid-19: real world data from the semi-covid-19 registry. J Clin Med. 2022;11(13):3769. doi: 10.3390/jcm11133769
   PubMed Web of Science ®Google Scholar
• Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022;194(7):E242–E251. doi: 10.1503/cmaj.211698
   PubMed Web of Science ®Google Scholar
• Padilla S, Polotskaya K, Fernández M, et al. Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation. J Antimicrob Chemother. 2022 [cited 2023 Mar 3];77(8):2257–2264. InternetAvailable from: https://academic.oup.com/jac/article/77/8/2257/6582904
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R, Henao-Restrepo AM, et al. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 - Interim WHO Solidarity trial results. N Engl J Med. 2021;384:497–511. doi: 10.1056/NEJMoa2023184
   PubMed Web of Science ®Google Scholar
• Karolyi M, Kaltenegger L, Pawelka E, et al. Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients: A propensity score matched analysis. Wien Klin Wochenschr. 2022 [cited 2023 Mar 3];134(23–24):883–891. InternetAvailable from: https://link.springer.com/10.1007/s00508-022-02098-9
   PubMed Web of Science ®Google Scholar
• Rajme-López S, Martinez-Guerra BA, Zalapa-Soto J, et al. Early outpatient treatment with remdesivir in patients at high risk for severe COVID-19: A prospective cohort study. Open Forum Infect Dis 2022; [cited 2023 Mar 6] 9:ofac502. https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofac502/6750022 10.1093/ofid/ofac502.
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386(4):305–315. doi: 10.1056/NEJMoa2116846
   PubMed Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057. doi: 10.1001/jama.2020.16349
   PubMed Web of Science ®Google Scholar
• Piccicacco N, Zeitler K, Ing A, et al. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the omicron surge. J Antimicrob Chemother. 2022;77(10):2693–2700. doi: 10.1093/jac/dkac256
   PubMed Web of Science ®Google Scholar
• Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10(1):e42–e51. doi: 10.1016/S2214-109X(21)00448-4
   PubMed Web of Science ®Google Scholar
• Kaizer AM, Shapiro NI, Wild J, et al. Lopinavir/Ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. Int J Infect Dis. 2023;128:223–229. doi: 10.1016/j.ijid.2022.12.028
   PubMed Web of Science ®Google Scholar
• Babayigit C, Kokturk N, Kul S, et al. The association of antiviral drugs with COVID-19 morbidity: the retrospective analysis of a nationwide COVID-19 cohort. Front Med. 2022;9:894126. doi: 10.3389/fmed.2022.894126
   Web of Science ®Google Scholar
• Karolyi M, Pawelka E, Mader T, et al. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: results from a real-life patient cohort. Wien Klin Wochenschr. 2021 [cited 2023 Mar 9];133(7–8):284–291. InternetAvailable from: https://link.springer.com/10.1007/s00508-020-01720-y
   PubMed Web of Science ®Google Scholar
• Ader F, Peiffer-Smadja N, Poissy J, et al. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021;27(12):1826–1837. doi: 10.1016/j.cmi.2021.05.020
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799. doi: 10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Horby PW, Mafham M, Bell JL, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345–1352. doi:10.1016/S0140-6736(20)32013-4
   PubMed Web of Science ®Google Scholar
• Wong CKH, ICH A, Lau KTK, et al. Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22:1681–1693. doi: 10.1016/S1473-3099(22)00507-2
   PubMed Web of Science ®Google Scholar
• Liu Y, Ge L, Fan S, et al. Disease progression of hospitalized elderly patients with omicron BA.2 Treated with molnupiravir. Infect Dis Ther. 2022 [cited 2023 Mar 9];11(6):2241–2251. InternetAvailable from: https://link.springer.com/10.1007/s40121-022-00716-7
   PubMed Web of Science ®Google Scholar
• Sinha S, K N, Suram VK, et al. Molnupiravir，efficacy and safety of molnupiravir in mild COVID-19 patients in India. Cureus. 2022;14:e31508. doi: 10.7759/cureus.31508
   PubMedGoogle Scholar
• Flisiak R, Zarębska-Michaluk D, Rogalska M, et al. Real-world experience with molnupiravir during the period of SARS-CoV-2 omicron variant dominance. Pharmacol Rep. 2022 [cited 2023 Mar 9];74(6):1279–1285. InternetAvailable from: https://link.springer.com/10.1007/s43440-022-00408-6
   PubMed Web of Science ®Google Scholar
• Yip T-F Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 Patients (COVID-19).
   Google Scholar
• Wong CKH, ICH A, Lau KTK, et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022 [[cited 2023 Mar 9]];400:1213–1222. InternetAvailable from https://linkinghub.elsevier.com/retrieve/pii/S0140673622015860
   PubMed Web of Science ®Google Scholar
• Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. [cited 2023 Mar 13]; Available from. 2023;23:696–705. Internet. 6. https://www.sciencedirect.com/science/article/pii/S1473309923000117 10.1016/S1473-3099(23)00011-7
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. Health system: a population-based cohort study. Ann Intern Med. 2023 [cited 2023 Mar 3];176(1):77–84. InternetAvailable from: https://www.acpjournals.org/doi/10.7326/M22-2141
   PubMed Web of Science ®Google Scholar
• Scott DP, Andy K, Arthur YK, et al. Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system. medRxiv: the preprint server for health sciences [Internet]. 2022 [cited 2023 Mar 14]; Available from: https://pubmed.ncbi.nlm.nih.gov/35734084/
   Google Scholar
• Pineda E, Singh J, Pineda MV, et al. Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study. Front Pharmacol. 2022 [[cited 2023 Aug 5]];13. InternetAvailable from: https://www.frontiersin.org/articles/10.3389/fphar.2022.1054644
   Web of Science ®Google Scholar
• Pitre T, Van Alstine R, Chick G, et al. Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis. CMAJ. 2022;194(28):E969–E980. doi: 10.1503/cmaj.220471
   PubMed Web of Science ®Google Scholar
• Hui DSC, Zumla A. Advances in the epidemiology, clinical features, diagnosis, clinical management and prevention of coronavirus disease 2019. Curr Opin Pulm Med. 2022;28(3):166–173. doi: 10.1097/MCP.0000000000000875
   PubMed Web of Science ®Google Scholar
• Angamo MT, Mohammed MA, Peterson GM. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. Infection. 2022;50(1):27–41. doi: 10.1007/s15010-021-01671-0
   PubMed Web of Science ®Google Scholar
• Lee TC, Murthy S, Del Corpo O, et al. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(9):1203–1210. doi: 10.1016/j.cmi.2022.04.018
   PubMed Web of Science ®Google Scholar
• Remdesivir and its antiviral activity against COVID-19: A systematic review - PubMed [Internet]. [cited 2023 Aug 11]. Available from: https://pubmed.ncbi.nlm.nih.gov/32838064/.
   Google Scholar
• Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses - PubMed [Internet]. [cited 2023 Aug 11]. Available from: https://pubmed.ncbi.nlm.nih.gov/32258351/.
   Google Scholar
• Arabi YM, Azoulay E, Al-Dorzi HM, et al. How the COVID-19 pandemic will change the future of critical care. Intensive care Med. 2021;47(3):282–291. doi: 10.1007/s00134-021-06352-y
   PubMed Web of Science ®Google Scholar
• Yu M, Wang D-C, Li S, et al. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019. J Med Virol. 2022;94(4):1513–1522. doi: 10.1002/jmv.27481
   PubMed Web of Science ®Google Scholar
• Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate covid-19: an exploratory randomized controlled trial. Med. 2020;1(1):105–113.e4. doi: 10.1016/j.medj.2020.04.001
   PubMed Web of Science ®Google Scholar
• Nie Z, Sun T, Zhao F. Safety and efficacy of antiviral drugs for the treatment of COVID-19: A systematic review. Infect Drug Resist. 2022;15:4457–4466. doi: 10.2147/IDR.S362946
   PubMed Web of Science ®Google Scholar
• Amstutz A, Speich B, Mentré F, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med InternetAvailable from. cited 2023 Mar 6;11:S453–464. https://linkinghub.elsevier.com/retrieve/pii/S221326002200528810.1016/S2213-2600(22)00528-8
   PubMed Web of Science ®Google Scholar
• Tian L, Pang Z, Li M, et al. Molnupiravir and its antiviral activity against COVID-19. Front Immunol. 2022;13:855496. doi: 10.3389/fimmu.2022.855496
   PubMed Web of Science ®Google Scholar
• Huang P, Liu T, Wu J, et al. Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID‐19: A systematic review and meta‐analysis of randomized control trials. J med virol. 2023 [[cited 2023 Mar 6]];95. InternetAvailable from: https://onlinelibrary.wiley.com/doi/10.1002/jmv.28621
   Web of Science ®Google Scholar
• Sutanto ST, Sinto R, Pasaribu A, et al. Molnupiravir and nirmatrelvir/ritonavir: The new Available antiviral options for COVID-19. Acta Med Indones. 2022;54(4):638–644.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Banerjee D, Singh A, et al. A clinical Insight on new discovered molecules and Repurposed drugs for the treatment of COVID-19. Vaccines (Basel). 2023;11(2):332. doi: 10.3390/vaccines11020332
   PubMed Web of Science ®Google Scholar
• Ganatra S, Dani SS, Ahmad J, et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019. Clin Infect Dis. 2023;76(4):563–572. doi: 10.1093/cid/ciac673
   PubMed Web of Science ®Google Scholar
• Navitha Reddy G, Jogvanshi A, Naikwadi S, et al. Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19. Exp Rev Anti-Infective Ther. 2023:1–13. doi: 10.1080/14787210.2023.2241638
   PubMed Web of Science ®Google Scholar
• Rabie AM. Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoVitris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs. New J Chem. 2021 [cited 2023 Jul 25];45(2):761–771. InternetAvailable from: https://pubs.rsc.org/en/content/articlelanding/2021/nj/d0nj03708g
   Web of Science ®Google Scholar